Pfizer Animal Health revenues surge in first quarter

Pfizer Animal Health has seen its revenue total for the first quarter of 2010 increase by 58 per cent year-on-year.

The pharmaceutical company’s veterinary medicines division revenue for the three-month period came to $846 million (560.9 million pounds), compared to $537 million in the year-ago quarter.

This total was boosted significantly by the addition of a number of former Wyeth products to Pfizer Animal Health’s portfolio, following the merger between Pfizer and Wyeth in October last year.

Across the group as a whole, the acquisition of Wyeth has a similar effect on revenues, with Pfizer revenues increasing by 54 per cent year-on-year to a total of $16.8 billion.

Jeff Kindler, chairman and chief executive officer of Pfizer, said: “Our results this quarter demonstrate the ability of our colleagues to deliver solid operational performance in a challenging environment, as well as to extract value for shareholders.”

The last quarter also saw Pfizer Animal Health agree to transfer a number of products to Lilly, including vaccines, parasiticides and feed additives, as part of the terms of the Wyeth merger.